Current Issues of Pharmacy and Medical Sciences

Lipoprotein-associated phospholipase A2 (Lp-PLA2 ) and high sensitivity C-reactive protein (hsCRP) levels, and extends coronary

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 4, Pages 453-456


Department of Laboratory Diagnostics Medical University of Lublin

DOI: 10.12923/j.2084-980X/26.4/a.23


A serum lipid profiles high sensitivity C-reactive protein (hsCRP) levels are established risk factors for atherosclerosis, and a powerful predictor of future myocardial infarction or cardiac death among apparently healthy individuals. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is know but not as cardiovascular risk factor. The aim of this study was to investigate serum Lp-PLA2 activity and arterial stiffness and others atherosclerosis biochemistry markers in patients with stable coronary artery disease. We studied 17 consecutive patients (women, n=6 and men, n=11), mean age was 61 years, with stable coronary artery disease (CAD), hospitalized in the Department of Cardiology Cardinal Wyszyński Hospital in Lublin in 2012 and 2013. The patients with acute and chronic kidney disease, liver diseases, active autoimmune disease, malignancy, thyroids diseases or alcohol disease were excluded from the analysis. The patients had worse laboratory parameters than the reference group. We showed significant positive correlation between serum level LpPLA2 and extends coronary disease in patients who had upper LpPLA2 levels in year observation. We concluded that dyslipidemia together with hsCRP and Lp-PLA2 and monitoring of its levels may be good markers to predict ACS or other CAD events and vessels lesions in asymptomatic patients with CAD. However, these results require further studies.



lipoprotein-associated phospholipase A2, high sensitivity C-reactive protein, coronary artery disease


  1. Azar RR, Aoun G, Fram DB, Waters DD, Wu AHB, Kiernan FJ.: Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am. J. Cardiol., 86, 205, 2000.
  2. Banasiak W., Gierelak G., Ponikowski P.: Stabilna choroba wieńcowa. Trudne pytania i wątpliwości kliniczne. Wydaw. MP., ISBN 978, 83-7430-163-3, 2008.
  3. Bogavac-Stanojević N., Jelić-Ivanović Z., Spasojević-Kalimanovska V., Spasić S., Kalimanovska-Oštrić D.: Lipid and inflammatory markers for the prediction of coronary artery disease: A multi-marker approach. Clin. Biochem., 40, 1000, 2007.
  4. Danesh J., Pepys M.B.: C-Reactive protein and coronary disease: is there a causal link? Circulation, 120, 2036, 2009.
  5. Danesh J., Wheeler J.G., Hirschfield G.M., et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med., 350,1387, 2004.
  6. Dullaart R., Constantinides A., Perton F.G.: Plasma cholesteryl ester transfer, but not cholesterol estrification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile. J. Clin. Endocrinol. Metab., 96(4),1077, 2011.
  7. Fox K., Alonso Garcia MA., Ardissino D.: Guidelines on the management of stable angina pectoris. Eur. Heart J. 7(8), 535, 2006.
  8. Khera A., de Lemos J.A., Peshock R.M., et al.: Relationship between C-reactive protein and subclinical atherosclerosis. The Dallas Heart Study. Circulation, 113, 38, 2006.
  9. Madjid M. and  Willerson J.T.: Inflammatory markers in coronary heart disease. Brit. Med. Bull., 100, 23, 2011.
  10. Pai J.K., Pischon T., Ma J., et al.: Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med., 351, 2599, 2004.
  11. Perk J., Backer G., Gohlke H., et al. : European Guidelines on cardiovascular disease prevention in clinical practice version 2012. Eur. Heart J., 33, 1635, 2012.
  12. Ridker P.M., Morrow D.A.: C-reactive protein, inflammation, and coronary risk. Cardiol. Clin., 21(3), 315, 2003.
  13. Sabatine M.S., Morrow D.A., O’Donoghue M., et al.: Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 27, 2463, 2007.
  14. Sadurska B, Szumiło M.: Fosfolipazy A w komórkach ssaków – budowa, właściwości, rola fizjologiczna i patologiczna. Post. Hig. Med. Dośw., 59, 116, 2005.
  15. Silva I.T., Mello A.P., Ma J.: Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a review. Lipid. Health. Dis., 10, 170, 2011.
  16. Swords J.N., Solomon C., Cushman C., et al.: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: results from the cardiovascular health study. Atherosclerosis, 209(2), 528, 2010.
  17. Taniguchi H. Momiyama Y., Ohmori R., et al.: Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease. Atherosclerosis, 178, 173, 2005.
  18. Zebrack JS, Muhlestein JB, Home BD, Anderson JL.: The Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J. Am. Coll. Cardiol., 39,632, 2002.


June 2020

Mon Tue Wed Thu Fri Sat Sun
01 02 03 04 05 06 07
08 09 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30